Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Opening Plenary: The Genome and Beyond

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7
Insights from cancer genomes into the mutational processes underlying cancer development
Michael R. Stratton
Wellcome Trust Sanger Inst., Cambridge, United Kingdom
from AACR Annual Meeting 2015 on April 19, 2015 9:30 AM-12:00 PM
Engineering the cancer genome
Tyler Jacks
David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, United States
from AACR Annual Meeting 2015 on April 19, 2015 9:30 AM-12:00 PM
Above the genome: The epigenome and its biology and translational potential
Stephen B. Baylin
Johns Hopkins University School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2015 on April 19, 2015 9:30 AM-12:00 PM
Using genomics to personalize cancer immunotherapy
Robert D. Schreiber
Washington University School of Medicine, St. Louis, MO, United States
from AACR Annual Meeting 2015 on April 19, 2015 9:30 AM-12:00 PM
Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, United States
from AACR Annual Meeting 2015 on April 19, 2015 9:30 AM-12:00 PM
Discussant: Phase III study of pembrolizumab (MK-3475) versus ipilimumab (Ribaset al.)
Jedd D. Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2015 on April 19, 2015 9:30 AM-12:00 PM
Dual targeting of BCR-ABL with ABL001: A novel potent allosteric ABL kinase inhibitor in combination with nilotinib suppresses the emergence of disease resistance in models of CML
William R. Sellers
Novartis Insts. for BioMedical Research, Cambridge, MA, United States
from AACR Annual Meeting 2015 on April 19, 2015 9:30 AM-12:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7